Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation

To characterize the course of patients with advanced sarcoidosis who have been listed for lung transplantation and to identify prognostic factors for death while they are on the waiting list. Retrospective cohort study. Tertiary-care university hospital. Forty-three patients with sarcoidosis who hav...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chest 2001-09, Vol.120 (3), p.873-880
Hauptverfasser: Arcasoy, Selim M., Christie, Jason D., Pochettino, Alberto, Rosengard, Bruce R., Blumenthal, Nancy P., Bavaria, Joseph E., Kotloff, Robert M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 880
container_issue 3
container_start_page 873
container_title Chest
container_volume 120
creator Arcasoy, Selim M.
Christie, Jason D.
Pochettino, Alberto
Rosengard, Bruce R.
Blumenthal, Nancy P.
Bavaria, Joseph E.
Kotloff, Robert M.
description To characterize the course of patients with advanced sarcoidosis who have been listed for lung transplantation and to identify prognostic factors for death while they are on the waiting list. Retrospective cohort study. Tertiary-care university hospital. Forty-three patients with sarcoidosis who have been listed for lung transplantation at the University of Pennsylvania Medical Center. A multivariable explanatory analysis using a Cox proportional hazards model was performed to determine risk factors that are independently associated with mortality while patients await transplantation. Twenty-three of the 43 patients (53%) died while awaiting transplantation. The survival rate of listed patients (as determined by the Kaplan-Meier method) was 66% at 1 year, 40% at 2 years, and 31% at 3 years. In a univariate analysis, the following factors were significantly associated with death on the waiting list: Pao2 ≤ 60 mm Hg (relative risk [RR], 3.4; 95% confidence interval [CI], 1.2 to 9.3); mean pulmonary artery pressure ≥ 35 mm Hg (RR, 3.2; 95% CI, 1.1 to 9.5); cardiac index≤ 2 L/min/m2 (RR, 2.8; 95% CI, 1.2 to 6.6), and right atrial pressure (RAP) ≥ 15 mm Hg (RR, 7.6; 95% CI, 3.0 to 19.3). Multivariable analysis revealed that RAP ≥ 15 mm Hg was the only independent prognostic variable (RR, 5.2; 95% CI, 1.6 to 16.7; p = 0.006). Twelve patients underwent lung transplantation. Survival after transplantation determined by the Kaplan-Meier method was 62% at both 1 and 2 years, and 50% at 3 years. Patients with advanced sarcoidosis awaiting lung transplantation have a high mortality rate with a median survival of < 2 years. Mortality is most closely linked to elevated RAP. While earlier referral may diminish the mortality rate of patients on the waiting list for transplantation, further improvements in posttransplantation outcomes will be necessary to ensure that this procedure truly bestows a survival benefit.
doi_str_mv 10.1378/chest.120.3.873
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71170532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0012369215501700</els_id><sourcerecordid>71170532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-dfddb8ab1313b95b43c9206805eac84566f208b2f98fcea876c5a843c25ef0633</originalsourceid><addsrcrecordid>eNp1kV2L1DAUhoMo7rh67Z0EQe86m4-mTS9lWD9gYAVXxKuQpsk2S6cZc1LFf-_RKYwI5iYEnveclyeEPOdsy2Wrr9zooWy5YFu51a18QDa8k7ySqpYPyYYxLirZdOKCPAG4Z_jmXfOYXHCu8Ai5IV93o83WFZ8jlOiA2nmgN0tx6eCBpkA_2hL9XIB-iWWkn2x2KQ4JItA9JvxAQ8p0v8x39DbbGY6TnQtG0vyUPAp2Av9svS_J57fXt7v31f7m3Yfdm33l6pqVagjD0Gvbc8ll36m-lq4TrNFMeet0rZomCKZ7ETodnLe6bZyyGimhfGCNlJfk9WnuMadvC-owhwjOT1jEpwVMy3nLlBQIvvwHvE9LnrGbEQyJjtUaoasT5HICyD6YY44Hm38azsxv5eaPcoPKjTSoHBMv1rFLf_DDmV8dI_BqBSw4OwXU5CKcuZo1SqjmvHqMd-OPmL2Bg50mHCtPS9e6f6_uTgmPfr9Hnw04_CznB0y7YoYU_1v7FxRxry8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>200539048</pqid></control><display><type>article</type><title>Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Arcasoy, Selim M. ; Christie, Jason D. ; Pochettino, Alberto ; Rosengard, Bruce R. ; Blumenthal, Nancy P. ; Bavaria, Joseph E. ; Kotloff, Robert M.</creator><creatorcontrib>Arcasoy, Selim M. ; Christie, Jason D. ; Pochettino, Alberto ; Rosengard, Bruce R. ; Blumenthal, Nancy P. ; Bavaria, Joseph E. ; Kotloff, Robert M.</creatorcontrib><description>To characterize the course of patients with advanced sarcoidosis who have been listed for lung transplantation and to identify prognostic factors for death while they are on the waiting list. Retrospective cohort study. Tertiary-care university hospital. Forty-three patients with sarcoidosis who have been listed for lung transplantation at the University of Pennsylvania Medical Center. A multivariable explanatory analysis using a Cox proportional hazards model was performed to determine risk factors that are independently associated with mortality while patients await transplantation. Twenty-three of the 43 patients (53%) died while awaiting transplantation. The survival rate of listed patients (as determined by the Kaplan-Meier method) was 66% at 1 year, 40% at 2 years, and 31% at 3 years. In a univariate analysis, the following factors were significantly associated with death on the waiting list: Pao2 ≤ 60 mm Hg (relative risk [RR], 3.4; 95% confidence interval [CI], 1.2 to 9.3); mean pulmonary artery pressure ≥ 35 mm Hg (RR, 3.2; 95% CI, 1.1 to 9.5); cardiac index≤ 2 L/min/m2 (RR, 2.8; 95% CI, 1.2 to 6.6), and right atrial pressure (RAP) ≥ 15 mm Hg (RR, 7.6; 95% CI, 3.0 to 19.3). Multivariable analysis revealed that RAP ≥ 15 mm Hg was the only independent prognostic variable (RR, 5.2; 95% CI, 1.6 to 16.7; p = 0.006). Twelve patients underwent lung transplantation. Survival after transplantation determined by the Kaplan-Meier method was 62% at both 1 and 2 years, and 50% at 3 years. Patients with advanced sarcoidosis awaiting lung transplantation have a high mortality rate with a median survival of &lt; 2 years. Mortality is most closely linked to elevated RAP. While earlier referral may diminish the mortality rate of patients on the waiting list for transplantation, further improvements in posttransplantation outcomes will be necessary to ensure that this procedure truly bestows a survival benefit.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.120.3.873</identifier><identifier>PMID: 11555523</identifier><identifier>CODEN: CHETBF</identifier><language>eng</language><publisher>Northbrook, IL: Elsevier Inc</publisher><subject>Adult ; Biological and medical sciences ; Cohort analysis ; Confidence intervals ; Female ; Humans ; Lung Transplantation ; Lung transplants ; Male ; Medical prognosis ; Medical sciences ; Middle Aged ; Mortality ; Multivariate Analysis ; Prognosis ; Proportional Hazards Models ; Pulmonary arteries ; Pulmonary fibrosis ; pulmonary hypertension ; Retrospective Studies ; Risk Factors ; Sarcoidosis ; Sarcoidosis, Pulmonary - mortality ; Sarcoidosis, Pulmonary - surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the respiratory system ; Waiting Lists</subject><ispartof>Chest, 2001-09, Vol.120 (3), p.873-880</ispartof><rights>2001 The American College of Chest Physicians</rights><rights>2002 INIST-CNRS</rights><rights>Copyright American College of Chest Physicians Sep 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-dfddb8ab1313b95b43c9206805eac84566f208b2f98fcea876c5a843c25ef0633</citedby><cites>FETCH-LOGICAL-c440t-dfddb8ab1313b95b43c9206805eac84566f208b2f98fcea876c5a843c25ef0633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14065256$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11555523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arcasoy, Selim M.</creatorcontrib><creatorcontrib>Christie, Jason D.</creatorcontrib><creatorcontrib>Pochettino, Alberto</creatorcontrib><creatorcontrib>Rosengard, Bruce R.</creatorcontrib><creatorcontrib>Blumenthal, Nancy P.</creatorcontrib><creatorcontrib>Bavaria, Joseph E.</creatorcontrib><creatorcontrib>Kotloff, Robert M.</creatorcontrib><title>Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation</title><title>Chest</title><addtitle>Chest</addtitle><description>To characterize the course of patients with advanced sarcoidosis who have been listed for lung transplantation and to identify prognostic factors for death while they are on the waiting list. Retrospective cohort study. Tertiary-care university hospital. Forty-three patients with sarcoidosis who have been listed for lung transplantation at the University of Pennsylvania Medical Center. A multivariable explanatory analysis using a Cox proportional hazards model was performed to determine risk factors that are independently associated with mortality while patients await transplantation. Twenty-three of the 43 patients (53%) died while awaiting transplantation. The survival rate of listed patients (as determined by the Kaplan-Meier method) was 66% at 1 year, 40% at 2 years, and 31% at 3 years. In a univariate analysis, the following factors were significantly associated with death on the waiting list: Pao2 ≤ 60 mm Hg (relative risk [RR], 3.4; 95% confidence interval [CI], 1.2 to 9.3); mean pulmonary artery pressure ≥ 35 mm Hg (RR, 3.2; 95% CI, 1.1 to 9.5); cardiac index≤ 2 L/min/m2 (RR, 2.8; 95% CI, 1.2 to 6.6), and right atrial pressure (RAP) ≥ 15 mm Hg (RR, 7.6; 95% CI, 3.0 to 19.3). Multivariable analysis revealed that RAP ≥ 15 mm Hg was the only independent prognostic variable (RR, 5.2; 95% CI, 1.6 to 16.7; p = 0.006). Twelve patients underwent lung transplantation. Survival after transplantation determined by the Kaplan-Meier method was 62% at both 1 and 2 years, and 50% at 3 years. Patients with advanced sarcoidosis awaiting lung transplantation have a high mortality rate with a median survival of &lt; 2 years. Mortality is most closely linked to elevated RAP. While earlier referral may diminish the mortality rate of patients on the waiting list for transplantation, further improvements in posttransplantation outcomes will be necessary to ensure that this procedure truly bestows a survival benefit.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cohort analysis</subject><subject>Confidence intervals</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Transplantation</subject><subject>Lung transplants</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate Analysis</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Pulmonary arteries</subject><subject>Pulmonary fibrosis</subject><subject>pulmonary hypertension</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sarcoidosis</subject><subject>Sarcoidosis, Pulmonary - mortality</subject><subject>Sarcoidosis, Pulmonary - surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the respiratory system</subject><subject>Waiting Lists</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kV2L1DAUhoMo7rh67Z0EQe86m4-mTS9lWD9gYAVXxKuQpsk2S6cZc1LFf-_RKYwI5iYEnveclyeEPOdsy2Wrr9zooWy5YFu51a18QDa8k7ySqpYPyYYxLirZdOKCPAG4Z_jmXfOYXHCu8Ai5IV93o83WFZ8jlOiA2nmgN0tx6eCBpkA_2hL9XIB-iWWkn2x2KQ4JItA9JvxAQ8p0v8x39DbbGY6TnQtG0vyUPAp2Av9svS_J57fXt7v31f7m3Yfdm33l6pqVagjD0Gvbc8ll36m-lq4TrNFMeet0rZomCKZ7ETodnLe6bZyyGimhfGCNlJfk9WnuMadvC-owhwjOT1jEpwVMy3nLlBQIvvwHvE9LnrGbEQyJjtUaoasT5HICyD6YY44Hm38azsxv5eaPcoPKjTSoHBMv1rFLf_DDmV8dI_BqBSw4OwXU5CKcuZo1SqjmvHqMd-OPmL2Bg50mHCtPS9e6f6_uTgmPfr9Hnw04_CznB0y7YoYU_1v7FxRxry8</recordid><startdate>20010901</startdate><enddate>20010901</enddate><creator>Arcasoy, Selim M.</creator><creator>Christie, Jason D.</creator><creator>Pochettino, Alberto</creator><creator>Rosengard, Bruce R.</creator><creator>Blumenthal, Nancy P.</creator><creator>Bavaria, Joseph E.</creator><creator>Kotloff, Robert M.</creator><general>Elsevier Inc</general><general>American College of Chest Physicians</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20010901</creationdate><title>Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation</title><author>Arcasoy, Selim M. ; Christie, Jason D. ; Pochettino, Alberto ; Rosengard, Bruce R. ; Blumenthal, Nancy P. ; Bavaria, Joseph E. ; Kotloff, Robert M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-dfddb8ab1313b95b43c9206805eac84566f208b2f98fcea876c5a843c25ef0633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cohort analysis</topic><topic>Confidence intervals</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Transplantation</topic><topic>Lung transplants</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate Analysis</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Pulmonary arteries</topic><topic>Pulmonary fibrosis</topic><topic>pulmonary hypertension</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sarcoidosis</topic><topic>Sarcoidosis, Pulmonary - mortality</topic><topic>Sarcoidosis, Pulmonary - surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the respiratory system</topic><topic>Waiting Lists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arcasoy, Selim M.</creatorcontrib><creatorcontrib>Christie, Jason D.</creatorcontrib><creatorcontrib>Pochettino, Alberto</creatorcontrib><creatorcontrib>Rosengard, Bruce R.</creatorcontrib><creatorcontrib>Blumenthal, Nancy P.</creatorcontrib><creatorcontrib>Bavaria, Joseph E.</creatorcontrib><creatorcontrib>Kotloff, Robert M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arcasoy, Selim M.</au><au>Christie, Jason D.</au><au>Pochettino, Alberto</au><au>Rosengard, Bruce R.</au><au>Blumenthal, Nancy P.</au><au>Bavaria, Joseph E.</au><au>Kotloff, Robert M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2001-09-01</date><risdate>2001</risdate><volume>120</volume><issue>3</issue><spage>873</spage><epage>880</epage><pages>873-880</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><coden>CHETBF</coden><abstract>To characterize the course of patients with advanced sarcoidosis who have been listed for lung transplantation and to identify prognostic factors for death while they are on the waiting list. Retrospective cohort study. Tertiary-care university hospital. Forty-three patients with sarcoidosis who have been listed for lung transplantation at the University of Pennsylvania Medical Center. A multivariable explanatory analysis using a Cox proportional hazards model was performed to determine risk factors that are independently associated with mortality while patients await transplantation. Twenty-three of the 43 patients (53%) died while awaiting transplantation. The survival rate of listed patients (as determined by the Kaplan-Meier method) was 66% at 1 year, 40% at 2 years, and 31% at 3 years. In a univariate analysis, the following factors were significantly associated with death on the waiting list: Pao2 ≤ 60 mm Hg (relative risk [RR], 3.4; 95% confidence interval [CI], 1.2 to 9.3); mean pulmonary artery pressure ≥ 35 mm Hg (RR, 3.2; 95% CI, 1.1 to 9.5); cardiac index≤ 2 L/min/m2 (RR, 2.8; 95% CI, 1.2 to 6.6), and right atrial pressure (RAP) ≥ 15 mm Hg (RR, 7.6; 95% CI, 3.0 to 19.3). Multivariable analysis revealed that RAP ≥ 15 mm Hg was the only independent prognostic variable (RR, 5.2; 95% CI, 1.6 to 16.7; p = 0.006). Twelve patients underwent lung transplantation. Survival after transplantation determined by the Kaplan-Meier method was 62% at both 1 and 2 years, and 50% at 3 years. Patients with advanced sarcoidosis awaiting lung transplantation have a high mortality rate with a median survival of &lt; 2 years. Mortality is most closely linked to elevated RAP. While earlier referral may diminish the mortality rate of patients on the waiting list for transplantation, further improvements in posttransplantation outcomes will be necessary to ensure that this procedure truly bestows a survival benefit.</abstract><cop>Northbrook, IL</cop><pub>Elsevier Inc</pub><pmid>11555523</pmid><doi>10.1378/chest.120.3.873</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0012-3692
ispartof Chest, 2001-09, Vol.120 (3), p.873-880
issn 0012-3692
1931-3543
language eng
recordid cdi_proquest_miscellaneous_71170532
source MEDLINE; Alma/SFX Local Collection
subjects Adult
Biological and medical sciences
Cohort analysis
Confidence intervals
Female
Humans
Lung Transplantation
Lung transplants
Male
Medical prognosis
Medical sciences
Middle Aged
Mortality
Multivariate Analysis
Prognosis
Proportional Hazards Models
Pulmonary arteries
Pulmonary fibrosis
pulmonary hypertension
Retrospective Studies
Risk Factors
Sarcoidosis
Sarcoidosis, Pulmonary - mortality
Sarcoidosis, Pulmonary - surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the respiratory system
Waiting Lists
title Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T22%3A53%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20and%20Outcomes%20of%20Patients%20With%20Sarcoidosis%20Listed%20for%20Lung%20Transplantation&rft.jtitle=Chest&rft.au=Arcasoy,%20Selim%20M.&rft.date=2001-09-01&rft.volume=120&rft.issue=3&rft.spage=873&rft.epage=880&rft.pages=873-880&rft.issn=0012-3692&rft.eissn=1931-3543&rft.coden=CHETBF&rft_id=info:doi/10.1378/chest.120.3.873&rft_dat=%3Cproquest_cross%3E71170532%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=200539048&rft_id=info:pmid/11555523&rft_els_id=S0012369215501700&rfr_iscdi=true